ADH1A and neoplasm: Subsequently, the safety and efficacy of ADH-1 as a single-agent therapy against neoplasms has been examined in phase I/II trials (NCT00264433, NCT00265057), as well as in combination with carboplatin, docetaxel or capecitabine (NCT00390676), and melphalan (LPAM) (NCT00421811).